Is Wall Street Bullish or Bearish on Bio-Techne Stock?

Headquartered in Minneapolis, Minnesota, Bio-Techne Corporation (TECH) is a major provider of life sciences tools and diagnostics. With a market cap of $11.45 billion, Bio-Techne is recognized for its comprehensive solutions in protein analysis, cell and gene therapy, and molecular diagnostics. The company’s innovative approach to biotechnology and clinical research enables its clients to advance scientific discoveries and develop effective treatments, helping to shape the future of healthcare and life sciences.

Shares of TECH have underperformed the broader market over the past year. The stock has declined 7.7% over this time frame, while the broader S&P 500 Index ($SPX) has rallied nearly 27.8%. In 2024, the stock is down 5.8%, while SPX has gained 17.8% on a YTD basis.